Transform how you analyse drug development risk
With the only transparent analysis of drug development risk at the product level.
Press Releases
Welcome to our press release archive. If you have questions about Evaluate or require data and expert insights to help support your editorial content, please see our Media Contacts.
Latest Press Releases
Evaluate Ltd. transforms pharma R&D risk assessment with launch of Product Specific PTRS
Breakthrough offering combines the power of machine learning with the transparency of Evaluate’s renowned analytical approach for the most accurate analysis of drug…
Vantage Half-Year Review 2019: Pharma and medtech mega-deals mask drop in M&A activity
The report, published today, analyses stock and market performance, M&A and the financing landscape during the first half of 2019
Innovation and unmet need drive prescription drug sales to $1.18tr by 2024: new report from Evaluate Ltd
“EvaluatePharma® World Preview 2019, Outlook to 2024” explores growth drivers, growth brakes and top industry performers.
Browse the archive
Median cost per patient for orphan drugs is 5.5 times higher than non-orphan drugs
Annual "EvaluatePharma Orphan Drug 2017 Report" sees continued growth (CAGR 2017 to 2022: +11.1%) for orphan drugs, approximately double overall prescription…
Pharma and Medtech sectors struggle in first half of 2016
Falling stock markets, political uncertainty and continued global economic weakness all contributed to a mixed first half for the pharma and medtech industries.
Evaluate Ltd named in 'Ones to recognise' category in Sunday Times annual BDO Profit Track 100
Life science market intelligence firm, Evaluate Ltd today announces that it has been selected as one of 10 companies in the “Ones to Recognise” category in the Sunday…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.